StockData
Turn Therapeutics Inc. logo

Turn Therapeutics Inc. (TTRX) stock

TTRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 2/30
$8.55+0.00 (0.00%)

Close on Nov 17, 2026Market cap $254.69MP/E –Yield –

Turn Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Turn Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.22M, up 409.4% year over year. For fiscal 2025 it was $265.57K, up 8.0% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$265.57K+8.0%
FY2024Dec 31, 2024$245.96K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$605.20K+281.3%
Q2 FY2026Jun 30, 2026$475.06K+657.9%
Q1 FY2026Mar 31, 2026$109.43K+1081.9%
Q4 FY2025Dec 31, 2025$34.93K+257.7%
Q3 FY2025Sep 30, 2025$158.70K+3.5%
Q2 FY2025Jun 30, 2025$62.68K–
Q1 FY2025Mar 31, 2025$9.26K–
Q4 FY2024Dec 31, 2024$9.77K–
Q3 FY2024Sep 30, 2024$153.28K–

More Turn Therapeutics figures

See a number that looks wrong?